Targeting conformational plasticity of protein kinases

ACS Chemical Biology

Volumn 10, Issue 1, 2015, Pages 190-200

  Tong, Michael ^a   Seeliger, Markus A ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; LIGAND; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

CONFORMATIONAL TRANSITION; ENERGY; ENZYME CONFORMATION; HUMAN; PLASTICITY; PREDICTION; PRIORITY JOURNAL; REVIEW; SIMULATION; ANIMAL; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; COMPUTATIONAL BIOLOGY; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 84921409244     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500870a     Document Type: Review

References (101)

1. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome Science 298, 1912-1934
2. Adams, J. A. (2001) Kinetic and catalytic mechanisms of protein kinases Chem. Rev. 101, 2271-2290
3. Noble, M. E., Endicott, J. A., and Johnson, L. N. (2004) Protein kinase inhibitors: insights into drug design from structure Science 303, 1800-1805
4. Endicott, J. A., Noble, M. E., and Johnson, L. N. (2012) The structural basis for control of eukaryotic protein kinases Annu. Rev. Biochem. 81, 587-613
5. Cowan-Jacob, S. W., Jahnke, W., and Knapp, S. (2014) Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases Future Med. Chem. 6, 541-561
6. Knapp, S. and Sundstrom, M. (2014) Recently targeted kinases and their inhibitors-the path to clinical trials Curr. Opin Pharmacol. 17, 58-63
7. Melnikova, I. and Golden, J. (2004) Targeting protein kinases Nat. Rev. Drug Discovery 3, 993-994
8. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289, 1938-1942
9. Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 1, 493-502
10. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39
11. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 29, 1039-1045
12. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1051
13. Liu, Y. and Gray, N. S. (2006) Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2, 358-364
14. Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., and Gray, N. S. (2014) Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9, 1230-1241
15. Masterson, L. R., Cheng, C., Yu, T., Tonelli, M., Kornev, A., Taylor, S. S., and Veglia, G. (2010) Dynamics connect substrate recognition to catalysis in protein kinase A Nat. Chem. Biol. 6, 821-828
16. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases Cell 109, 275-282
17. Dar, A. C. and Shokat, K. M. (2011) The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling Annu. Rev. Biochem. 80, 769-795
18. Agius, M. P. and Soellner, M. B. (2014) Modulating noncatalytic function with kinase inhibitors Chem. Biol. 21, 569-571
19. Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., and Duggan, M. E. (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 15, 761-764
20. Hughes, J. P., Rees, S., Kalindjian, S. B., and Philpott, K. L. (2011) Principles of early drug discovery Br. J. Pharmacol. 162, 1239-1249
21. Zhao, Z., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huber, H. E., Duggan, M. E., and Lindsley, C. W. (2008) Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity Bioorg. Med. Chem. Lett. 18, 49-53
22. Barnett, S. F., Defeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K. M., Jones, R. E., Kahana, J. A., Kral, A. M., Leander, K., Lee, L. L., Malinowski, J., McAvoy, E. M., Nahas, D. D., Robinson, R. G., and Huber, H. E. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors Biochem. J. 385, 399-408
23. Kar, G., Keskin, O., Gursoy, A., and Nussinov, R. (2010) Allostery and population shift in drug discovery Curr. Opin Pharmacol. 10, 715-722
24. Hatzivassiliou, G., Liu, B., OBrien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., Toy, K., Ha, C., Zhou, W., Song, K., Friedman, L. S., Amler, L. C., Hampton, G. M., Moffat, J., Belvin, M., and Lackner, M. R. (2012) ERK inhibition overcomes acquired resistance to MEK inhibitors Mol. Cancer Ther. 11, 1143-1154
25. Shukla, D., Meng, Y., Roux, B., and Pande, V. S. (2014) Activation pathway of Src kinase reveals intermediate states as targets for drug design Nat. Commun. 5, 3397
26. Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E. T., Hammaren, H., Yamashita, K., Silvennoinen, O., Shaw, D. E., and Hubbard, S. R. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase Nat. Struct Mol. Biol. 21, 579-584
27. Shan, Y., Kim, E. T., Eastwood, M. P., Dror, R. O., Seeliger, M. A., and Shaw, D. E. (2011) How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133, 9181-9183
28. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 5, 730-739
29. Mobley, D. L. and Dill, K. A. (2009) Binding of small-molecule ligands to proteins: "what you see" is not always "what you get" Structure 17, 489-498
30. Fabbro, D. and Garcia-Echeverria, C. (2002) Targeting protein kinases in cancer therapy Curr. Opin. Drug Discovery Dev. 5, 701-712
31. Steichen, J. M., Iyer, G. H., Li, S., Saldanha, S. A., Deal, M. S., Woods, V. L., Jr., and Taylor, S. S. (2010) Global consequences of activation loop phosphorylation on protein kinase A J. Biol. Chem. 285, 3825-3832
32. Steichen, J. M., Kuchinskas, M., Keshwani, M. M., Yang, J., Adams, J. A., and Taylor, S. S. (2012) Structural basis for the regulation of protein kinase A by activation loop phosphorylation J. Biol. Chem. 287, 14672-14680
33. Fang, Z., Grutter, C., and Rauh, D. (2013) Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features ACS Chem. Biol. 8, 58-70
34. Kornev, A. P., Haste, N. M., Taylor, S. S., and Eyck, L. F. (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc. Natl. Acad. Sci. U. S. A. 103, 17783-17788
35. Kornev, A. P., Taylor, S. S., and Ten Eyck, L. F. (2008) A helix scaffold for the assembly of active protein kinases Proc. Natl. Acad. Sci. U. S. A. 105, 14377-14382
36. Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., and Eck, M. J. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11, 217-227
37. Stamos, J., Sliwkowski, M. X., and Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277, 46265-46272
38. Chaikuad, A., Tacconi, E. M., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., and Knapp, S. (2014) A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics Nat. Chem. Biol. 10, 853-860
39. Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., Long, B., Liu, J., Dinunzio, E., Windsor, W., Zhang, R., Zhao, S., Angagaw, M. H., Pinheiro, E. M., Desai, J., Xiao, L., Shipps, G., Hruza, A., Wang, J., Kelly, J., Paliwal, S., Gao, X., Babu, B. S., Zhu, L., Daublain, P., Zhang, L., Lutterbach, B. A., Pelletier, M. R., Philippar, U., Siliphaivanh, P., Witter, D., Kirschmeier, P., Bishop, W. R., Hicklin, D., Gilliland, D. G., Jayaraman, L., Zawel, L., Fawell, S., and Samatar, A. A. (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors Cancer Discovery 3, 742-750
40. Gajiwala, K. S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Weinrich, S., Kath, J. C., and Stewart, A. (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition Structure 21, 209-219
41. Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., and Daley, G. Q. (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine Nat. Struct. Mol. Biol. 15, 1109-1118
42. Xu, W., Harrison, S. C., and Eck, M. J. (1997) Three-dimensional structure of the tyrosine kinase c-Src Nature 385, 595-602
43. Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., and Kuriyan, J. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain PLoS Biol. 4, e144
44. Seeliger, M. A., Nagar, B., Frank, F., Cao, X., Henderson, M. N., and Kuriyan, J. (2007) c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty Structure 15, 299-311
45. Seeliger, M. A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D. E., Shah, N. P., Kuriyan, J., and Maly, D. J. (2009) Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Res. 69, 2384-2392
46. Kleiner, R. E., Dumelin, C. E., Tiu, G. C., Sakurai, K., and Liu, D. R. (2010) In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors J. Am. Chem. Soc. 132, 11779-11791
47. Georghiou, G., Kleiner, R. E., Pulkoski-Gross, M., Liu, D. R., and Seeliger, M. A. (2012) Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles Nat. Chem. Biol. 8, 366-374
48. Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., Radaelli, F., Ciccone, F., Tiribelli, M., di Lorenzo, R., Caracciolo, C., Izzo, B., Pane, F., Saglio, G., Baccarani, M., Martinelli, G., and Leukemia, G. W. P. o. C. M. (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin. Cancer Res. 12 (-) 7374-7379
49. Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., Mueller, W. T., Delaney, A., Omer, C., Sebolt-Leopold, J., Dudley, D. T., Leung, I. K., Flamme, C., Warmus, J., Kaufman, M., Barrett, S., Tecle, H., and Hasemann, C. A. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat. Struct. Mol. Biol. 11, 1192-1197
50. Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., Przybranowski, S. A., Sebolt-Leopold, J., Van Becelaere, K., Doherty, A. M., Kennedy, R. M., Marston, D., Howard, W. A., Jr., Smith, Y., Warmus, J. S., and Tecle, H. (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Bioorg. Med. Chem. Lett. 18, 6501-6504
51. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K. J., Rusnak, D. W., Gilmer, T. M., and Shewchuk, L. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64, 6652-6659
52. Qiu, C., Tarrant, M. K., Choi, S. H., Sathyamurthy, A., Bose, R., Banjade, S., Pal, A., Bornmann, W. G., Lemmon, M. A., Cole, P. A., and Leahy, D. J. (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase Structure 16, 460-467
53. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., and Regan, J. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 9, 268-272
54. Regan, J., Pargellis, C. A., Cirillo, P. F., Gilmore, T., Hickey, E. R., Peet, G. W., Proto, A., Swinamer, A., and Moss, N. (2003) The kinetics of binding to p38MAP kinase by analogues of BIRB 796 Bioorg. Med. Chem. Lett. 13, 3101-3104
55. Zuccotto, F., Ardini, E., Casale, E., and Angiolini, M. (2010) Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 53, 2681-2694
56. Hari, S. B., Merritt, E. A., and Maly, D. J. (2013) Sequence determinants of a specific inactive protein kinase conformation Chem. Biol. 20, 806-815
57. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discovery 5, 835-844
58. Namboodiri, H. V., Bukhtiyarova, M., Ramcharan, J., Karpusas, M., Lee, Y., and Springman, E. B. (2010) Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases Biochemistry 49, 3611-3618
59. Simard, J. R., Getlik, M., Grutter, C., Pawar, V., Wulfert, S., Rabiller, M., and Rauh, D. (2009) Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors J. Am. Chem. Soc. 131, 13286-13296
60. Simard, J. R., Grutter, C., Pawar, V., Aust, B., Wolf, A., Rabiller, M., Wulfert, S., Robubi, A., Kluter, S., Ottmann, C., and Rauh, D. (2009) High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha J. Am. Chem. Soc. 131, 18478-18488
61. Simard, J. R., Kluter, S., Grutter, C., Getlik, M., Rabiller, M., Rode, H. B., and Rauh, D. (2009) A new screening assay for allosteric inhibitors of cSrc Nat. Chem. Biol. 5, 394-396
62. Getlik, M., Simard, J. R., Termathe, M., Grutter, C., Rabiller, M., van Otterlo, W. A., and Rauh, D. (2012) Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38alpha kinase PLoS One 7, e39713
63. Schneider, R., Becker, C., Simard, J. R., Getlik, M., Bohlke, N., Janning, P., and Rauh, D. (2012) Direct binding assay for the detection of type IV allosteric inhibitors of Abl J. Am. Chem. Soc. 134, 9138-9141
64. Fang, Z., Simard, J. R., Plenker, D., Nguyen, H. D., Phan, T., Wolle, P., Baumeister, S., and Rauh, D. (2014) Discovery of Inter-Domain Stabilizers-A Novel Assay System for Allosteric Akt Inhibitors Acs Chem. Biol. 10.1021/cb500355c
65. Navratilova, I., Macdonald, G., Robinson, C., Hughes, S., Mathias, J., Phillips, C., and Cook, A. (2012) Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action J. Biomol. Screening 17, 183-193
66. Kitagawa, D., Gouda, M., and Kirii, Y. (2014) Quick evaluation of kinase inhibitors by surface plasmon resonance using single-site specifically biotinylated kinases J. Biomol. Screening 19, 453-461
67. Salafsky, J. S. (2006) Detection of protein conformational change by optical second-harmonic generation J. Chem. Phys. 125, 074701
68. Salafsky, J. S. (2007) Second-harmonic generation for studying structural motion of biological molecules in real time and space Phys. Chem. Chem. Phys. 9, 5704-5711
69. Nucciotti, V., Stringari, C., Sacconi, L., Vanzi, F., Fusi, L., Linari, M., Piazzesi, G., Lombardi, V., and Pavone, F. S. (2010) Probing myosin structural conformation in vivo by second-harmonic generation microscopy Proc. Natl. Acad. Sci. U. S. A. 107, 7763-7768
70. Chen, H., Huang, Z., Dutta, K., Blais, S., Neubert, T. A., Li, X., Cowburn, D., Traaseth, N. J., and Mohammadi, M. (2013) Cracking the molecular origin of intrinsic tyrosine kinase activity through analysis of pathogenic gain-of-function mutations Cell Rep. 4, 376-384
71. Vogtherr, M., Saxena, K., Hoelder, S., Grimme, S., Betz, M., Schieborr, U., Pescatore, B., Robin, M., Delarbre, L., Langer, T., Wendt, K. U., and Schwalbe, H. (2006) NMR characterization of kinase p38 dynamics in free and ligand-bound forms Angew. Chem., Int. Ed. Engl. 45, 993-997
72. Sours, K. M., Xiao, Y., and Ahn, N. G. (2014) Extracellular-regulated kinase 2 is activated by the enhancement of hinge flexibility J. Mol. Biol. 426, 1925-1935
73. Xiao, Y., Lee, T., Latham, M. P., Warner, L. R., Tanimoto, A., Pardi, A., and Ahn, N. G. (2014) Phosphorylation releases constraints to domain motion in ERK2 Proc. Natl. Acad. Sci. U. S. A. 111, 2506-2511
74. Vajpai, N., Strauss, A., Fendrich, G., Cowan-Jacob, S. W., Manley, P. W., Grzesiek, S., and Jahnke, W. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib J. Biol. Chem. 283, 18292-18302
75. Ali, M. M., Bagratuni, T., Davenport, E. L., Nowak, P. R., Silva-Santisteban, M. C., Hardcastle, A., McAndrews, C., Rowlands, M. G., Morgan, G. J., Aherne, W., Collins, I., Davies, F. E., and Pearl, L. H. (2011) Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response EMBO J. 30, 894-905
76. Wang, L., Perera, B. G., Hari, S. B., Bhhatarai, B., Backes, B. J., Seeliger, M. A., Schurer, S. C., Oakes, S. A., Papa, F. R., and Maly, D. J. (2012) Divergent allosteric control of the IRE1alpha endoribonuclease using kinase inhibitors Nat. Chem. Biol. 8, 982-989
77. Maly, D. J. and Papa, F. R. (2014) Druggable sensors of the unfolded protein response Nat. Chem. Biol. 10, 892-901
78. Ghosh, R., Wang, L., Wang, E. S., Perera, B. G., Igbaria, A., Morita, S., Prado, K., Thamsen, M., Caswell, D., Macias, H., Weiberth, K. F., Gliedt, M. J., Alavi, M. V., Hari, S. B., Mitra, A. K., Bhhatarai, B., Schurer, S. C., Snapp, E. L., Gould, D. B., German, M. S., Backes, B. J., Maly, D. J., Oakes, S. A., and Papa, F. R. (2014) Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress Cell 158, 534-548
79. Korennykh, A. V., Egea, P. F., Korostelev, A. A., Finer-Moore, J., Zhang, C., Shokat, K. M., Stroud, R. M., and Walter, P. (2009) The unfolded protein response signals through high-order assembly of Ire1 Nature 457, 687-693
80. Rodriguez, J. and Crespo, P. (2011) Working without kinase activity: phosphotransfer-independent functions of extracellular signal-regulated kinases Sci. Signal 4, re3
81. Hari, S. B., Merritt, E. A., and Maly, D. J. (2014) Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases Chem. Biol. 21, 628-635
82. Zhang, J., Adrian, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., Guo, G. R., Ding, Q., Okram, B., Choi, Y., Wojciechowski, A., Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y., Bursulaya, B., Azam, M., Manley, P. W., Engen, J. R., Daley, G. Q., Warmuth, M., and Gray, N. S. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463, 501-506
83. Skora, L., Mestan, J., Fabbro, D., Jahnke, W., and Grzesiek, S. (2013) NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors Proc. Natl. Acad. Sci. U. S. A. 110, E4437-4445
84. Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., Reich, M. F., Shen, R., Shi, X., Tsou, H. R., Wang, Y. F., and Wissner, A. (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res. 64, 3958-3965
85. Yoshimura, N., Kudoh, S., Kimura, T., Mitsuoka, S., Matsuura, K., Hirata, K., Matsui, K., Negoro, S., Nakagawa, K., and Fukuoka, M. (2006) EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib Lung Cancer 51, 363-368
86. Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., and Buggy, J. J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U. S. A. 107, 13075-13080
87. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., and Gray, N. S. (2013) Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 20, 146-159
88. Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. O., Dror, R. O., Kuriyan, J., and Shaw, D. E. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase Proc. Natl. Acad. Sci. U. S. A. 106, 139-144
89. Schneider, E. V., Bottcher, J., Huber, R., Maskos, K., and Neumann, L. (2013) Structure-kinetic relationship study of CDK8/CycC specific compounds Proc. Natl. Acad. Sci. U. S. A. 110, 8081-8086
90. Miller, D. C., Lunn, G., Jones, P., Sabnis, Y., Davies, N. L., and Driscoll, P. (2012) Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target Medchemcomm 3, 449-452
91. Sharp, K., Fine, R., and Honig, B. (1987) Computer simulations of the diffusion of a substrate to an active site of an enzyme Science 236, 1460-1463
92. Setny, P., Baron, R., Michael Kekenes-Huskey, P., McCammon, J. A., and Dzubiella, J. (2013) Solvent fluctuations in hydrophobic cavity-ligand binding kinetics Proc. Natl. Acad. Sci. U. S. A. 110, 1197-1202
93. Hurst, D. P., Grossfield, A., Lynch, D. L., Feller, S., Romo, T. D., Gawrisch, K., Pitman, M. C., and Reggio, P. H. (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor J. Biol. Chem. 285, 17954-17964
94. Lin, Y. L. and Roux, B. (2013) Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases J. Am. Chem. Soc. 135, 14741-14753
95. Lin, Y. L., Meng, Y., Jiang, W., and Roux, B. (2013) Explaining why Gleevec is a specific and potent inhibitor of Abl kinase Proc. Natl. Acad. Sci. U. S. A. 110, 1664-1669
96. Aleksandrov, A. and Simonson, T. (2010) Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases J. Biol. Chem. 285, 13807-13815
97. Hari, S. B., Perera, B. G., Ranjitkar, P., Seeliger, M. A., and Maly, D. J. (2013) Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src ACS Chem. Biol. 8, 2734-2743
98. Betzi, S., Alam, R., Martin, M., Lubbers, D. J., Han, H., Jakkaraj, S. R., Georg, G. I., and Schonbrunn, E. (2011) Discovery of a potential allosteric ligand binding site in CDK2 ACS Chem. Biol. 6, 492-501
99. Martin, M. P., Alam, R., Betzi, S., Ingles, D. J., Zhu, J. Y., and Schonbrunn, E. (2012) A novel approach to the discovery of small-molecule ligands of CDK2 Chembiochem 13, 2128-2136
100. Foda, Z. H., Shan, Y., Kim, E., Shaw, D. E., and Seeliger, M. A. (In press) A dynamically coupled allosteric network underlies binding cooperativity in Src kinase, Nat. Commun.
101. Lee, K. P., Dey, M., Neculai, D., Cao, C., Dever, T. E., and Sicheri, F. (2008) Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing Cell 132, 89-100